These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12837675)

  • 41. A 10-year perspective on donepezil.
    Cheewakriengkrai L; Gauthier S
    Expert Opin Pharmacother; 2013 Feb; 14(3):331-8. PubMed ID: 23316713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders.
    Schultz BR; Takeshita J; Goebert D; Takeshita S; Lu BY; Guilloux A; Higa J
    Psychogeriatrics; 2017 Nov; 17(6):423-429. PubMed ID: 28387023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease.
    Hager K; Calabrese P; Frölich L; Göbel C; Berger FM
    Dement Geriatr Cogn Disord; 2003; 15(4):189-98. PubMed ID: 12626851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy no advantage in Alzheimer's treatment.
    Harv Health Lett; 2012 Jun; 37(8):8. PubMed ID: 22774260
    [No Abstract]   [Full Text] [Related]  

  • 45. [Post-marketing observational study of donepezil].
    Ibach B
    Krankenpfl J; 2005; 43(1-3):25. PubMed ID: 15912820
    [No Abstract]   [Full Text] [Related]  

  • 46. 'Awakenings' in demented patients.
    Hori K; Oda T; Tominaga I; Inada T
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):237. PubMed ID: 12667174
    [No Abstract]   [Full Text] [Related]  

  • 47. Early Alzheimer's disease.
    Finucane TE
    N Engl J Med; 2010 Oct; 363(18):1773; author reply 1773. PubMed ID: 21038515
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Withdrawal syndrome after donepezil cessation in a patient with dementia.
    Bidzan L; Bidzan M
    Neurol Sci; 2012 Dec; 33(6):1459-61. PubMed ID: 22249402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An open-label trial of donepezil (aricept) in the treatment of persons with mild traumatic brain injury.
    Kaye NS; Townsend JB; Ivins R
    J Neuropsychiatry Clin Neurosci; 2003; 15(3):383-4; author reply 384-5. PubMed ID: 12928519
    [No Abstract]   [Full Text] [Related]  

  • 54. Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index.
    Lee C; Lee K; Yu H; Ryu SH; Moon SW; Han C; Lee JY; Lee YM; Kim SG; Kim KW; Lee DW; Kim SY; Lee SY; Bae JN; Jung YE; Kim JL; Kim BS; Shin IS; Kim YH; Kim BJ; Kang HS; Myung W; Carroll BJ; Kim DK
    J Clin Psychopharmacol; 2017 Aug; 37(4):401-404. PubMed ID: 28590369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Donepezil in vascular dementia: a viewpoint by Sandra E. Black.
    Black SE
    Drugs Aging; 2003; 20(15):1138. PubMed ID: 14651438
    [No Abstract]   [Full Text] [Related]  

  • 56. Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.
    Borroni B; Colciaghi F; Pastorino L; Pettenati C; Cottini E; Rozzini L; Monastero R; Lenzi GL; Cattabeni F; Di Luca M; Padovani A
    Arch Neurol; 2001 Mar; 58(3):442-6. PubMed ID: 11255448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
    Kircher TT; Erb M; Grodd W; Leube DT
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):1006-13. PubMed ID: 16286445
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease.
    Bottiggi KA; Salazar JC; Yu L; Caban-Holt AM; Ryan M; Schmitt FA
    Am J Geriatr Psychiatry; 2007 Apr; 15(4):357-9. PubMed ID: 17384320
    [No Abstract]   [Full Text] [Related]  

  • 59. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients.
    Johnell K; Fastbom J
    Drugs Aging; 2008; 25(10):871-7. PubMed ID: 18808211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).
    Ballard C; Brown R; Fossey J; Douglas S; Bradley P; Hancock J; James IA; Juszczak E; Bentham P; Burns A; Lindesay J; Jacoby R; O'Brien J; Bullock R; Johnson T; Holmes C; Howard R
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):726-33. PubMed ID: 19700946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.